Talking Medicines argues that AI agents can improve how information is monitored, analysed and acted on, but that agents alone are not enough. In healthcare, the quality of the output still depends on the models, methodologies and domain knowledge sitting underneath the automation.
Life sciences data is complex. Patient and healthcare professional conversations often contain specialist terminology, treatment experiences, behavioural signals and clinical context that general-purpose AI may not interpret reliably enough on its own.
Talking Medicines has built its platform around this problem. Its technology uses proprietary AI, healthcare-specific data science and domain expertise to turn unstructured conversations into structured intelligence.
The platform includes healthcare classification models, behavioural intelligence, emotional analysis, evidence-based scoring frameworks and specialist linguistic models and ontologies. These tools are designed to identify what patients and healthcare professionals are saying, why it matters and how those signals may change over time.
Agentic AI sits above that intelligence layer. The agents can coordinate different models, monitor conversations across channels, identify emerging topics and trigger alerts, reports or follow-up workflows.
Instead of relying on manual analysis or isolated tools, organisations can use agents to connect multiple analytical processes and move relevant information towards decision-makers more quickly.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
